About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Treatment -Resistant Neovascular Age-Related Macular Degeneration

NCT02332941·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Washington University School of Medicine

Age

41–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Over the age of 40
Patients who have a diagnosis of wet age-related macular degeneration
Patients who have a central visual acuity ,20/200
Patients who have been deemed "treatment-resistant" at the discreation of the treating physician

You may not be if

Patients with treatment failure for neovascular AMD
Patients who have tried multiple anti-vegf medication without anatomical or objective improvement

The record

StatusCompleted

PhasePhase 1

Taking part5

StartedAug 2014

UpdatedJun 3, 2015

Conditions

Macular Degeneration

Where1

Washington University School of Medicine
St Louis, Missouri, United States

Clareo Health | Treatment -Resistant Neovascular Age-Related Macular Degeneration